CDH1 hypermethylation: a potential molecular pathway for invasiveness in glioblastoma.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
03 Jul 2023
03 Jul 2023
Historique:
medline:
4
7
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
aheadofprint
Résumé
Glioblastoma is the most aggressive central nervous system primary tumor. Prognosis is poor, mainly due to the malignant characteristics of the tumor, such as high cell proliferation and invasiveness. CDH1 hypermethylation is linked to the invasive potential in various cancer types, but its importance is still unknown in glioblastoma. In this context, the methylation status of CDH1 was analyzed using MSP-PCR (Methylation-specific Polymerase Chain Reaction) in glioblastoma (n = 34) and normal glial tissue samples (n = 11). CDH1 hypermethylation was found in 39.4% (13/34) of the tumor samples and none of the normal glial tissue, suggesting a relation between CDH1 hypermethylation and glioblastoma (P = 0.0195). Finally, this study showed unprecedented information that could contribute to clarifying the molecular pathways involved in the invasiveness and aggressiveness of this type of cancer.
Identifiants
pubmed: 37401481
doi: 10.1097/CEJ.0000000000000824
pii: 00008469-990000000-00075
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Biswas P, Karim SN, Hossain AI, Roy S, Hossain SA, Saleh AF (2021). E-cadherin Gene (CDH1) expression in low grade astrocytoma. Mymensingh Med J 30:315–322.
Cunha MLV, Maldaun MVC (2019). Metastasis from glioblastoma multiforme: a meta-analysis. Rev Assoc Méd Bras 65:424–433.
D’Urso PI, D’Urso OF, Storelli C, Catapano G, Gianfreda CD, Montinaro A, et al. (2011). Retrospective protein expression and epigenetic inactivation studies of CDH1 in patients affected by low-grade glioma. J Neurooncol 104:113–118.
Figueiredo J, Melo S, Carneiro P, Moreira AM, Fernandes MS, Ribeiro AS, et al. (2019). Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet 56:199–208.
Förster A, Brand F, Banan R, Hüneburg R, Weber CAM, Ewert W, et al. (2021). Rare germline variants in the E-cadherin gene CDH1 are associated with the risk of brain tumors of neuroepithelial and epithelial origin. Acta Neuropathol 142:191–210.
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. (1991). E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113:173–185.
Gately L, McLachlan SA, Dowling A, Philip J (2017). Life beyond a diagnosis of glioblastoma: a systematic review of the literature. J Cancer Surviv 11:447–452.
Gonzalez Castro LN, Wesseling P (2020). The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neurooncol Pract 8:4–10.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003.
Liu J, Sun X, Qin S, Wang H, Du N, Li Y, et al. (2016). CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. Oncol Lett 11:2635–2643.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. (2021). 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251.
McMahon KW, Karunasena E, Ahuja N (2017). The roles of DNA methylation in the stages of cancer. Cancer J 23:257–261.
Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, et al. (2010). PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 20:298–300.
Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, et al. (2003). Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2:24.
Robertson FL, Marqués-Torrejón MA, Morrison GM, Pollard SM (2019). Experimental models and tools to tackle glioblastoma. Dis Model Mech 12:9.
Sambrook J, Fritsch EF, Maniatis T (1989). Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press vol. 2, p. 368.
Shenoy S (2019). CDH1 (E-Cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management. Cancer Manag Res 11:10477–10486.
Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF (2001). Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 48:367–371.